Andrea Maria D'ARmini

Andrea Maria D'ARmini

Auto-generated profile, based on publicly available information

Andrea Maria D'ARmini

Division of Cardiac Surgery II and Chronic Thromboembolic Pulmonary Hypertension Center, Cardio-Thoracic and Vascular Department, Foundation IRCCS Policlinico San Matteo, Pavia, Italy (A.M.D.).

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Circulation
Verified
Journal Article
Open access
MDMarion Delcroix
Marion Delcroix
JPJoanna Pepke-Zaba
Joanna Pepke-Zaba
ADAndrea M. D’aRmini
Andrea M. D’aRmini
EFElie Fadel
Elie Fadel
SGStefan Guth
Stefan Guth
Irene M. LangIrene M. Lang
Irene M. Lang
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension (CTEPH) registry, conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term survival of patients with CTEPH. Since then, 2 additional treatments for inoperable CTEPH have become available: balloon pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator riociguat. The current registry aimed to evaluate the effect of these new therapeutic approaches in a worldwide context. METHODS: Participation in this international global registry included 34 centers in 20 countries. Between February 2015 and September 2016, 1009 newly diagnosed, consecutive patients were included and followed until September 2019. RESULTS: Overall, 605 patients (60%) underwent PEA and 185 (18%) underwent BPA; 76% of the 219 remaining patients not receiving mechanical intervention (ie, neither PEA nor BPA) were treated with pulmonary hypertension drugs. Of patients undergoing PEA and BPA, 38% and 78% also received drugs for pulmonary hypertension, respectively. Median age at diagnosis was higher in the BPA and No PEA/BPA groups than in the PEA group: 66 and 69, respectively, versus 60 years. Pulmonary vascular resistance (PVR) was similar in all groups, with an average of 643 dynes.s.cm −5 . During the observation period (>3 years; ≤5.6 years), death was reported in 7%, 11%, and 27% of patients treated by PEA and BPA, and those receiving no mechanical intervention ( P <0.001). In Kaplan-Meier analysis, 3-year survival was 94%, 92%, and 71% in the 3 groups, respectively. PEA 3-year survival improved by 5% from that observed between 2007 and 2012. There was no survival difference in patients receiving vitamin K antagonists and non–vitamin K oral anticoagulants ( P =0.756). In Cox regression, reduced mortality was associated with: PEA and BPA in the global cohort; history of venous thromboembolism and lower PVR in the PEA group; lower right atrial pressure in the BPA group; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well as functional class in the group receiving no mechanical intervention. CONCLUSIONS: This second international CTEPH registry reveals important improvement in patient survival since the introduction of BPA and an approved drug for pulmonary hypertension. The type of anticoagulation regimen did not influence survival. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02656238.

28 December 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
VMVallerie V. McLaughlin
Vallerie V. McLaughlin
PJPavel Jansa
Pavel Jansa
JNJens E. Nielsen-Kudsk
Jens E. Nielsen-Kudsk
MHMichael Halank
Michael Halank
GSGérald Simonneau
Gérald Simonneau
ADAndrea M. D’aRmini
Andrea M. D’aRmini
Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH. We performed an open-label, uncontrolled, single-arm, early access study in which 300 adult patients with inoperable or persistent/recurrent CTEPH received riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid. Patients switching from unsatisfactory prior pulmonary arterial hypertension (PAH)-targeted therapy (n = 84) underwent a washout period of at least 3 days before initiating riociguat. The primary aim was to assess the safety and tolerability of riociguat, with World Health Organization functional class and 6-min walking distance (6MWD) as exploratory efficacy endpoints. In total, 262 patients (87%) completed study treatment and entered the safety follow-up (median treatment duration 47 weeks). Adverse events were reported in 273 patients (91%). The most frequently reported serious adverse events were syncope (6%), right ventricular failure (3%), and pneumonia (2%). There were five deaths, none of which was considered related to study medication. The safety and tolerability of riociguat was similar in patients switched from other PAH-targeted therapies and those who were treatment naïve. In patients with data available, mean ± standard deviation 6MWD had increased by 33 ± 42 m at Week 12 with no clinically relevant differences between the switched and treatment-naïve subgroups. Riociguat was well tolerated in patients with CTEPH who were treatment naïve, and in those who were switched from other PAH-targeted therapies. No new safety signals were observed. ClinicalTrials.org NCT01784562 . Registered February 4, 2013.

1 January 2013 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MARCO MORSOLINIMARCO MORSOLINI
MARCO MORSOLINI
GZGiuseppe Zattera
Giuseppe Zattera
FMFederica Meloni
Federica Meloni
ADAndrea Maria D'ARmini
Andrea Maria D'ARmini

11 July 2020 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
FAFilippo Antonacci
Filippo Antonacci
LMLeslie J. T. Masiglat
Leslie J. T. Masiglat
EBErmelinda Borrelli
Ermelinda Borrelli
MSMaurizio Salati
Maurizio Salati
ADAndrea M. D'ARmini
Andrea M. D'ARmini
Pasquale TotaroPasquale Totaro
Pasquale Totaro
Acute pulmonary embolism (APE) is a well‐described complication following surgical procedures. The incidence of such a complication can be related to the presence of a peculiar patient's condition. Cryoglobulinemia, which consists in the presence of one or more immunoglobulins in the serum that precipitate at temperatures below 37°C and redissolve on warming, seems to increase the risk of thrombotic events. Treatment options of APE, according to clinical severity, include systemic thrombolysis, surgical embolectomy, and systemic anticoagulation. Thrombolysis is considered the first‐line treatment, whereas surgery is reserved in case of extremely‐compromised hemodynamic conditions related to massive central embolism, and in case of contraindication to thrombolysis. Here, we report a case of acute massive pulmonary embolism occurring at the end of a surgical procedure for a thymic carcinoma resection, in a patient with cryoglobulinemia, which required an emergent surgical pulmonary embolectomy.

27 November 2012 in Transplantation
Verified
Journal Article
Open access
RFR. Fiocchi
R. Fiocchi
ABA. Branzi
A. Branzi
MFM. Frigerio
M. Frigerio
Giacomo GerosaGiacomo Gerosa
Giacomo Gerosa
GLG. Leonardi
G. Leonardi
LPLuciano Potena
Luciano Potena